Development of a specific antibody therapy for newly identified CD34 antigen-negative leukemic stem cell niche

• Project/Area Number: 25461438
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Kansai Medical University
• Principal Investigator: FUJIOKA Tatsuya 関西医科大学, 医学部, 講師 (70403045)
• Co-Investigator(Kenkyū-buntansha): SONODA Yoshiaki 関西医科大学, 医学部, 教授 (60206688)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 白血病幹細胞 / 抗体療法

Outline of Final Research Achievements

We conducted a study for development of antibody therapy against leukemic stem cells (LSC) that cause a recurrence of leukemia. At first, we identified CD34-negative LSCs that are more undifferentiated than LSCs hitherto known. Then, antibodies against CD34-negative LSCs were produced. Analyzing of target epitopes of this produced antibodies, an antigen were identified as a promising target for a new leukemic treatment. This antibody exerted anti-leukemic cell effects in in vitro experiments.

Research Products

• [Remarks] 新規白血病幹細胞の同定と抗体療法の開発
  • URL: http://www3.kmu.ac.jp/hygiene/html/research_1.html